250+ Clinical Trials: Hosted at Alpha Clinics for CIRM funded and other research. 2000+ Patients Enrolled: Pioneers who participated in a clinical trial at an Alpha Clinic. 40+ Diseases & Conditions: ...

The California Cell and Gene Therapy Manufacturing Network was established by CIRM to expand the manufacturing capabilities necessary to bring stem cell and gene therapies from foundational research ...

CIRM is supporting a network of 11 Shared Resources Laboratories (SRLs) for Stem Cell-Based Modeling, an important component of CIRM’s Infrastructure Program designed to address challenges that hinder ...

Research Objective We propose to discover a novel, genetically modified hematopoietic stem cell based treatment for Danon disease, a rare lysosomal storage disease that affects the heart. Impact As ...

Cystinosis is a rare disease that primarily affects children and young adults, and leads to premature death, usually in early adulthood. Patients inherit defective copies of a gene called CTNS,… ...

Members of the public are invited to attend CIRM governing board meetings and to provide comment on agenda items. On this page we list agendas for all public meetings, including meetings of the ...

The ICOC may adopt interim regulations exempted from compliance with the procedures set forth in the APA. The interim regulations are adopted by the ICOC and remain in effect for 270 days unless ...

The mission of California Institute for Regenerative Medicine (CIRM) is to accelerate world class science to deliver transformative regenerative medicine treatments in an equitable manner to a diverse ...

The mission of the California Institute for Regenerative Medicine (CIRM) is to accelerate world class science to deliver transformative regenerative medicine treatments in an equitable manner to a ...

The following information will help you comply with CIRM regulations and find information about our forms and policies. If you have questions that aren’t addressed on this page contact your Grants ...

Title 17 California Code of Regulations Section 100080 (f) designates all human pluripotent stem cell lines derived in accordance with the CIRM regulations as “acceptably derived.” These cell lines ...

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox ...